- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient Burden Associated With Uncomplicated UTIs
Panelists discuss how patients with recurrent urinary tract infections (UTIs) describe significant burdens including constant anxiety about symptom onset, disruption to work and social life, financial strain from frequent office visits and medications, frustration with treatment-resistant infections, embarrassment discussing symptoms, sexual dysfunction, relationship difficulties, and substantial mental health impacts such as depression and diminished quality of life.
EP: 1.Differentiating Uncomplicated and Complicated Urinary Tract Infections (UTIs)
EP: 2.Trends in Uncomplicated UTIs
EP: 3.Exploring Social Determinants of Health in Uncomplicated UTIs
EP: 4.Examining Uncomplicated UTI Recurrence
EP: 5.Role of Patients’ Education in Uncomplicated UTIs
EP: 6.Patient Burden Associated With Uncomplicated UTIs
EP: 7.Minimizing Antibiotic Resistance Development in Uncomplicated UTIs
EP: 8.Examining the Need for Updated Guidelines for Uncomplicated UTIs
EP: 9.Comparing Standard-of-Care Antibiotics for Uncomplicated UTIs
EP: 10.Patient Factors Influencing Antibiotic Selection in Uncomplicated UTIs
EP: 11.Recurrence Rates in Uncomplicated UTIs
EP: 12.Economic Burden Associated With Uncomplicated UTIs
EP: 13.Important Updates in the Management of Uncomplicated UTIs
EP: 14.Exploring Novel Options for the Management of Uncomplicated UTIs
EP: 15.Comparing Newer With Traditional Agents in Uncomplicated UTIs
EP: 16.Payer-Related Barriers With Therapies Used for Uncomplicated UTIs
EP: 17.Final Panel Thoughts on Uncomplicated UTI Management
Video content above is prompted by the following:
- How do patients with recurrent UTIs describe the burden of their condition, particularly in relation to treatment resistance, the frequency of office visits, and the impact on their daily lives and mental well-being?
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
